Zealand Pharma — November 2022

[Svingtraderen]

tak

[exitnu]

Operator virkede da også uøvet

[EliotSpitzer]

Det var en fin lille gennemgang af situationen. Finacial targets bliver fastholdt og ingen overraskelser. Jeg troet at BI var lidt længere fremme end det som blev fremlagt. Men det er min fejl at jeg ikke havde styr på dette.

[exitnu]

Tydeligvis en glitch - desværre.

[exitnu]

Luk i 189,50 & -1,66%. God aften

[ProinvestorNEWS]

Zealand Pharma Q3: Omsætning dykker og underskud vokser https://www.proinvestor.com/investornyt/903219/zealand-pharma-q3-omsaetning-dykker-og-underskud-vokser

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[exitnu]

God morgen

[ungeee]

22.21 - ikke for at lave ballade, men hvilken planet er du på? Eller er du ude på sjov

[exitnu]

"Jeg kan, på ingen måde, se at selskabet skulle være en investering værd"

JA der er fx sket alt for lidt i Q3:

[exitnu]

Announced positive topline results from the pivotal Phase 3 EASE-1 trial of glepaglutide, a long-acting GLP-2 analogue designed for subcutaneous delivery via auto-injector, in patients with short bowel syndrome (SBS).

[exitnu]

Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes (T2D) at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD).

[exitnu]

Presented results from the Phase 3 clinical trial of dasiglucagon in congenital hyperinsulinism (CHI) at the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE).

[exitnu]

Completed dose escalation in the ongoing Phase 1a single ascending dose (SAD) trial of ZP8396, a long-acting amylin analogue.

[exitnu]

Announced a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE (dasiglucagon) for injection.

[exitnu]

Personligt synes jeg at Zealand Pharma har overpræsteret. Alt går deres/vores vej ...

[exitnu]

@Pensionisten - gider du venligst uddybe - tak!

[exitnu]

Plus disse fire begivenheder:

Presented preclinical data at the Annual Meeting of the Obesity Society (Obesity Week). Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906 (GCGR/GLP-1R) in patients with T2D at Obesity Week. Phase 2 trial of BI 456906 in patients with non-alcoholic steatohepatitis (NASH). Received gross proceeds of DKK 786 million from a directed issue and private placement.

[ProinvestorNEWS]